Quince Therapeutics
QNCX
37 hedge funds and large institutions have $104M invested in Quince Therapeutics in 2019 Q2 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.05% more ownership
Funds ownership: 0% → 0.05% (+0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SUT
SC US (TTGP)
Menlo Park,
California
|
+$31.1M |
| 2 |
AI
Alphabet Inc
Mountain View,
California
|
+$13.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.22M |
| 4 |
BlackRock
New York
|
+$4.16M |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$2.99M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| $189K | +$131K | +22 | New |
|
27
New York State Common Retirement Fund
Albany,
New York
| $128K | +$89.6K | +15 | New |
|
28
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $92K | +$65.7K | +11 | New |
|
|
AIG
29
American International Group
New York
| $78K | +$53.8K | +9 | New |
|
30
JP Morgan Chase
New York
| $78K | +$59.7K | +10 | New |
|
|
ACA
31
Atlas Capital Advisors
Jackson,
Wyoming
| $63.8K | +$47.8K | +8 | New |
|
32
Citigroup
New York
| $34K | +$23.9K | +4 | New |
|
|
SO
33
STRS Ohio
Columbus,
Ohio
| $34K | +$23.9K | +4 | New |
|
34
Legal & General Group
London,
United Kingdom
| $20K | +$11.9K | +2 | New |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| $16K | +$11.9K | +2 | New |
|
|
CCA
36
Catalyst Capital Advisors
Huntington,
New York
| $14K | +$11.9K | +2 | New |
|
|
AIP
37
Ameritas Investment Partners
Lincoln,
Nebraska
| $11K | +$5.97K | +1 | New |
|
38
BNP Paribas Financial Markets
Paris,
France
| $595 | – | – | – |
|
QNCX Hedge Fund Activity: Q2 2019 in Review
37 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q2 2019, worth a combined $104M.
Buyers outnumbered sellers: 37 funds opened new QNCX positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was SC US (TTGP), opening a new position worth an estimated $31.1M.
- 37 institutional investors held Quince Therapeutics (QNCX) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $104M of Quince Therapeutics stock for Q2 2019.
- 37 funds opened new Quince Therapeutics positions in Q2 2019 and 0 closed out, a net change of +37 holders.
- The largest Quince Therapeutics buyer in Q2 2019 was SC US (TTGP), an estimated $31.1M added.
Based on aggregated 13F filings for Q2 2019.